Leesburg, VA, April 15, 2012 --(PR.com
)-- K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, is showcasing a complete anterior cervical fixation portfolio at the 2012 American Association of Neurological Surgeons Annual Scientific Meeting (AANS) in Miami.
“With the recent additions of BLUE RIDGE™ Hybrid and PYRENEES® Translational to our product offering, K2M is now able to address all segments of the cervical fixation market and build upon our comprehensive portfolio as a leader in the global spine market,” stated Eric Major, K2M’s President and CEO.
The latest addition to K2M’s portfolio of constrained and translational cervical plates, the BLUE RIDGE Hybrid Cervical Plate System, features a simple to use nitinol locking mechanism that engages seamlessly during screw insertion without additional locking steps. The system also supports fixed and variable screws, providing the flexibility to create constrained, semi-constrained, or hybrid screw constructs.
According to James Robinson, MD, designing neurosurgeon, “BLUE RIDGE provides incredible ease of use. You don’t feel any resistance as the screw passes the self-locking mechanism and, yet, it’s securely locked. Additionally, the unlocking tool is simple and intuitive.”
Another product introduced at the end of 2011 was K2M’s PYRENEES® Translational Cervical Plate System. The plate is characterized by a unidirectional ratchet mechanism at each level to allow for controlled settling of the patient’s anatomy. This system is part of a family of spine products, including PYRENEES Constrained, a low-profile cervical plate system with a 1.5 mm leading edge. Featuring K2M’s revolutionary tifix® Locking Technology, neither product requires an additional locking mechanism, as each screw head forms an autogenic lock to the plate upon insertion.
K2M will be showcasing all three products at AANS Booth #1510.
K2M, Inc. is an innovative spinal device company committed to the research, development, and commercialization of simplified solutions for the treatment of complex spinal pathologies and minimally invasive procedures. The company is recognized as a worldwide leader in providing unique technologies for the treatment of deformity, degenerative, trauma, and tumor spinal patients. K2M’s product development pipeline includes: spinal stabilization systems, minimally invasive systems, biologics, and other advancing technologies such as motion preservation, annular repair, and nucleus replacement. Additional information is available online at www.K2M.com.
Find K2M on Facebook: https://www.facebook.com/K2MInc
Follow K2M on Twitter: http://twitter.com/K2MInc